PSI-352938 is a nucleoside derivative patented by Pharmasset, Inc. as an antiviral agent. PSI-352938 acts as a novel cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine-5'-monophosphate with potent anti-HCV activity. PSI-352938 inhibits HCV genotype (GT) 1b replicon replication with 50% effective concentrations (EC50s) of 0.13 ± 0.076 μM, and active against GT 1a and 2a replicons and infectious viruses PSI-352938 retained full activity against replicons containing the S282T substitution, which confers resistance to certain 2'-substituted nucleoside/nucleotide analogs. In April 2013, because of hepatic toxicity, Gilead Sciences discontinued the development of PSI-352938.

Bibapcitide, a 26 amino acid, bis-succinimidomethyl ether-linked dimer of the peptide apcitide is a component of lyophilized kit having the trade name AcuTect. When pertechnetate (99mTcO4-) is added to the AcuTect radiopharmaceutical kit and the resulting kit is heated, [99mTcO] apcitide forms. This kit is used for scintigraphic imaging of veins to identify acute venous thrombosis in the lower legs.

Peforelin, a decapeptide analog of the natural gonadotropin acts as the natural gonadotropin-releasing hormone (GnRH) agonist. This drug under the brand name Maprelin is used in veterinary to stimulate the reproductive function of sows after weaning piglets in the syndrome of sexual depression.

Aldose reductase-IN-1 is an inhibitor of aldose reductase